Meissa to bring synthetic RSV vaccine to clinic with $30M series A

With preclinical data in hand and manufacturing capabilities established, Meissa raised $30 million in a series A from new investor Morningside Ventures to bring its synthetic biology-based universal RSV vaccine

Read the full 300 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE